Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Aug 02, 2022 12:57pm
186 Views
Post# 34866091

RE:Fireside Chat on August 10

RE:Fireside Chat on August 10Perhaps the ice is thawing between TH and Canaccord as Canaccord gave TH a decent time slot. Their analyst also indicated he was warming up to cancer in his last report. 

TH owes a favor to Canaccord after their analyst stepped up and wrote a favorable report following the listing on NASDAQ. I imagine if there is good cancer news before they need to draw down the remaining amount of the Marathon loan in June to pay off the convert, TH might take advantage of any bounce in the share price to raise some equity capital, avoid additional debt and square things up with Canaccord.   

jfm1330 wrote: The last time, Paul said a lot of things, but his timelines were totally wrong for phase Ia. Anyway. Maybe we can get a couple of bits of interesting infos.


<< Previous
Bullboard Posts
Next >>